Sentences with phrase «for epidermal growth factor»

Current studies focus mainly on two receptor systems - the mast cell surface receptor, FcεRI, and the receptor for epidermal growth factor that operate in immunological and cell proliferation responses.

Targeting of AMSH to endosomes is required for epidermal growth factor receptor degradation.

Alice Shaw recalls a signal moment in 2004 — just as she was finishing her oncology fellowship at MIT — when scientists discovered that mutations in a gene for epidermal growth factor receptor (EGFR) were the culprits in about 10 to 15 percent of lung cancer patients.

The study, called «Molecular Determinants of Drug - Specific Sensitivity for Epidermal Growth Factor Receptor (EGFR) Exon 19 and 20 Mutants in Non-Small Cell Lung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patients.

Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker - guided treatment is cost - effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.

Not exact matches

Findings of the research, published April 22 in the journal Mucosal Immunology, reveal that a substance found in animal and human breast milk called epidermal growth factor, or EGF, blocks the activation of a protein responsible for unlocking the damaging immune cascade that culminates in NEC, a disease marked by the swift and irreversible death of intestinal tissue that remains one of the most - challenging - to - treat conditions.

About 15 to 20 % of breast cancers are classified as «triple negative,» so called because these tumors do not express three key proteins that are biomarkers and / or drug targets for breast cancer: the estrogen receptor, the progesterone receptor, and HER2 (a member of the epidermal growth factor receptor family).

Recent findings suggest a novel positron emission tomography (PET) imaging approach determining epidermal growth factor receptor (EGFR) mutation status for improved lung cancer patient management.

For example, epidermal growth factor (EGFR) mutations may result in sensitivity to drugs that are EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib or gefitinib, whereas individuals with the EGFR T790M mutation are more resistant to these drugs.

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for patients with advanced non-small cell lung cancer (NSCLC) who have mutations in the EGFR gene.

Researchers at the San Diego Supercomputer Center (SDSC) and the Moores Cancer Center at the University of California, San Diego, have described for the first time the molecular mechanism of cancer development caused by well - known «resistance» mutations in the gene called epidermal growth factor receptor (EGFR).

Triple - negative cancers are so called because they do not express receptors for the hormones estrogen and progesterone, nor for HER2 (human epidermal growth factor 2), and hence patients with these cancers are not candidates for treatment with modern hormonal therapies or the highly effective HER2 - targeted drug Herceptin (trastuzumab).

For years researchers have been developing molecular imaging techniques that visualize hormonally active breast cancer cells — specifically those testing positive for human epidermal growth factor receptor 2 (HERFor years researchers have been developing molecular imaging techniques that visualize hormonally active breast cancer cells — specifically those testing positive for human epidermal growth factor receptor 2 (HERfor human epidermal growth factor receptor 2 (HER2).

PALLAS: Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR +) / Human Epidermal Growth Factor Receptor 2 (HER2)- Negative Early Breast Cancer

With this technology, they could watch for responses as cancer cells responded to signals from EGFR (epidermal growth factor receptor).

GEP testing is recommended for patients with early - stage, node - negative, estrogen receptor (ER)-- positive, human epidermal growth factor 2 (HER2)-- negative cancers.

A major challenge for assessing driver mutations, such as epidermal growth factor receptor (EGFR) mutations, in advanced disease is the scarcity of suitable biopsy tissue for molecular testing.

Each subtype was classified by gene expression clustering, and showed specific patterns of genetic alterations, particularly for four genes: platelet - derived growth factor receptor alpha (PDGFRA), isocitrate dehydrogenase 1 (IDH1), epidermal growfth factor receptor (EGFR), and neurofibromin 1 (NF1).

Chemotherapy is a key part of the standard treatment regimen for triple - negative breast cancer patients whose cancer lacks expression of estrogen and progesterone receptors and the human epidermal growth factor receptor 2...

Triple negative breast cancer is a type of breast cancer that does not express receptors for the hormones estrogen and progesterone, or for human epidermal growth factor.

The human epidermal growth factor receptor - 2 (HER2) gene makes proteins responsible for maintaining healthy cell growth, division and repair of breast tissue.

In addition to RIPK2 binding as part of this computer - based (initial) screening, we selected compounds that inhibited epidermal growth factor receptor (IC50 values > 1000 nM; weak inhibitory activity) along with weak binding interactions in the EGFR and c - ABL binding sites, two common off - targets for previously identified RIPK2 inhibitors.

The discovery of how the epidermal growth factor receptor (EGFR) is activated offers insight into how current EGFR - blocking drugs interact with the receptor and an important avenue for the...

These results, also presented at the 2015 European Cancer Congress (ECC2015, abstract # 5BA) today, which involve the group of 1,626 patients with a Recurrence Score between 0 and 10, demonstrated that 99.3 percent of node - negative, estrogen receptor (ER)- positive, human epidermal growth factor receptor 2 (HER2)- negative patients who met accepted guidelines for recommending chemotherapy in addition to hormonal therapy, had no distant recurrence at five years after treatment with hormonal therapy alone.

Many women are «triple negative» No one yet knows precisely why, but African - American women are roughly twice as likely as white women to have triple - negative breast cancer — so called because tumor cells in this particularly aggressive form of the disease test negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER - 2).

Peptide growth factors are constantly present in the gastrointestinal tract, being secreted by glands; for example, Epidermal Growth Factor (EGF) from the salivary glands, or ingested in foodstuffs such as milk and cologrowth factors are constantly present in the gastrointestinal tract, being secreted by glands; for example, Epidermal Growth Factor (EGF) from the salivary glands, or ingested in foodstuffs such as milk and coloGrowth Factor (EGF) from the salivary glands, or ingested in foodstuffs such as milk and colostrum.

In highly proliferative lesions with increased Ki67, estrogen receptor was negative, but human epidermal growth factor receptor 2 was usually positive with a distribution that was similar to that reported for human intraepithelial lesions (7).